secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087035
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune Q1 FY2025: $53.8M net loss, $469.1M cash; RP1 BLA on track for 2H 2024
--------------------------------------------------------------------------------

- Net loss $53.8M for Q1 ended June 30, 2024, up from $49.6M YoY; R&D expenses $43.0M versus $40.4M.
- Cash, cash equivalents and short-term investments $469.1M; $96.7M net PIPE financing supports operations into 2H 2026.
- Pre-BLA meeting with FDA scheduled for September 2024; RP1 BLA submission planned for 2H 2024.
- First patient enrollment in Phase 3 confirmatory IGNYTE-3 trial for RP1 in anti-PD1 failed melanoma expected Q3 2024.
- Protocol finalized for registration-directed study of RP2 in uveal melanoma; Phase 2 HCC trial first patient expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924087035/0001104659-24-087035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924087035/tm2421132d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer